Targeting and promoting atherosclerosis regression using hybrid membrane coated nanomaterials via alleviated inflammation and enhanced autophagy
Source abstract
Abstract
ABSTRACT Atherosclerosis is the leading cause of death and disability worldwide, which is lack of efficient strategy for targeted therapy. In this work, we reported a hybrid membrane coated graphene oxide quantum dots (GOQDs) nanomaterial loading atorvastatin (AT) to achieve targeted atherosclerosis therapy. In this biomimetic nanomaterial, macrophages membrane (Møm) was used to extend the half-life of AT and enhance the accumulation of AT in the atherosclerotic plaques. Meanwhile, red blood cell membrane (RBCm) was adopted to reduce the amount of Møm usage. Furthermore, hyaluronic acid (HA) was inserted into the hybrid membrane to enhance the internalization of nanomaterial into activated macrophages of atherosclerotic plaques. In vitro assay demonstrated that this nanomaterial can release AT in an acidic pH-responsive manner. In vivo assay demonstrated that both long-term low-dose and short-term high-dose regimens with favorable safety can effectively inhibit the development of the early atherosclerosis and markedly regress the progression of advanced atherosclerotic plaques, respectively. Molecular mechanism exploration indicated that the anti-atherosclerosis effect of the nanomaterial was mediated by alleviating inflammation to reduce lipid influx and enhancing autophagy to promote cholesterol efflux. Overall, this biomimetic nanomaterial provides an alternative for developing safe and efficient strategy for atherosclerosis therapy.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Extracellular vesicles in disease · Protease and Inhibitor Mechanisms · Phagocytosis and Immune Regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Atherosclerosis, nature reviews10.1038/s41572-019-0106-z ↗
2. Regulation of lipid droplet cholesterol efflux from macrophage foam cells10.1161/ATVBAHA.111.240705 ↗
3. Inflammation and plaque vulnerability10.1111/joim.12406 ↗
4. Pharmacological modulation of cell death in atherosclerosis: a promising approach towards plaque stabilization?10.1111/j.1476-5381.2011.01342.x ↗
5. The safety of statins in clinical practice10.1016/S0140-6736(07)60716-8 ↗
6. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering10.1161/01.ATV.21.1.115 ↗
7. Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis10.1016/j.addr.2021.01.005 ↗
8. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles10.1039/C5CS00541H ↗
9. High density lipoprotein mimicking nanoparticles for atherosclerosis10.1186/s40580-019-0214-1 ↗
10. Noncovalent functionalization of graphene and graphene oxide for energy materials, biosensing, catalytic, and biomedical applications10.1021/acs.chemrev.5b00620 ↗
11. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo10.1038/nnano.2016.269 ↗
12. A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases10.1016/j.biomaterials.2019.119605 ↗
13. Anti-PEG immunity: emergence, characteristics, and unaddressed questions10.1002/wnan.1339 ↗
14. Immunosuppressive and anti-inflammatory properties of engineered nanomaterials10.1111/bph.12722 ↗
15. Progress of cell-derived biomimetic drug delivery systems for cancer therapy10.1002/adtp.201800053 ↗
16. A self-driven bioinspired nanovehicle by leukocyte membrane-hitchhiking for early detection and treatment of atherosclerosis10.1016/j.biomaterials.2020.119963 ↗
17. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines10.1038/s41467-020-16439-7 ↗
18. Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery10.1039/C9BM01392J ↗
19. Biomimetic nanotherapies: red blood cell based core-shell structured nanocomplexes for atherosclerosis management
20. Hyaluronic acid nanoparticles for active targeting atherosclerosis10.1016/j.biomaterials.2015.02.089 ↗
21. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition10.1016/j.actbio.2020.06.025 ↗
22. A graphene quantum dot-based FRET system for nuclear-targeted and real-time monitoring of drug delivery10.1039/C5NR03454J ↗
23. Erythrocyte-cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal/chemotherapy of melanoma10.1021/acsnano.7b08355 ↗
24. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization10.1002/adma.201606209 ↗
25. Acidification of the intimal fluid: the perfect storm for atherogenesis10.1194/jlr.R050252 ↗
26. A RBC membrane-camouflaged biomimetic nanoplatform for enhanced chemo-photothermal therapy of cervical cancer10.1039/C9TB02937K ↗
27. Atherosclerosis and inflammation: overview and updates10.1042/CS20180306 ↗
28. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree10.1161/01.ATV.14.1.133 ↗
29. Improved in vitro and in vivo biocompatibility of graphene oxide through surface modification: poly(acrylic acid)-functionalization is superior to pegylation10.1021/acsnano.6b00539 ↗
30. Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects10.1016/j.nantod.2014.04.008 ↗
31. Engineering cell membrane-based nanotherapeutics to target inflammation
32. The CD44-HA axis and inflammation in atherosclerosis: a temporal perspective10.1016/j.matbio.2018.05.007 ↗
33. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine10.1039/D0CS01127D ↗
34. Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment10.1038/nmat4497 ↗
35. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies10.1016/j.nantod.2011.02.003 ↗
36. Endocytic mechanisms of graphene oxide nanosheets in osteoblasts, hepatocytes and macrophages10.1021/am5031598 ↗
37. Kobiyama · Atherosclerosis, Circ. Res. · 2018 · 123 · 111810.1161/CIRCRESAHA.118.313816 ↗
38. Basic biology of oxidative stress and the cardiovascular system: part 1 of a 3-part series10.1016/j.jacc.2017.05.034 ↗
39. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
40. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis10.1161/CIRCULATIONAHA.113.005015 ↗
41. Vascular smooth muscle cells in atherosclerosis10.1161/CIRCRESAHA.115.306361 ↗
42. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies10.1161/CIRCRESAHA.114.302355 ↗
43. Pathology of human plaque vulnerability: mechanisms and consequences of intraplaque haemorrhages10.1016/j.atherosclerosis.2014.03.020 ↗
44. Regulatory t cells license macrophage pro-resolving functions during atherosclerosis regression10.1161/CIRCRESAHA.119.316461 ↗
45. Targeting foam cell formation in atherosclerosis: therapeutic potential of natural products10.1124/pr.118.017178 ↗
46. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation10.1038/ncomms4065 ↗
47. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
48. Defective autophagy in atherosclerosis: to die or to senesce?10.1155/2018/7687083 ↗
49. Regulation of macrophage immunometabolism in atherosclerosis10.1038/s41590-018-0113-3 ↗
50. Artemisinin alleviates atherosclerotic lesion by reducing macrophage inflammation via regulation of AMPK/NF-kappaB/NLRP3 inflammasomes pathway10.1080/1061186X.2019.1616296 ↗
51. Nanoparticle-based “Two-pronged” approach to regress atherosclerosis by simultaneous modulation of cholesterol influx and efflux10.1016/j.biomaterials.2020.120333 ↗
52. SR-BI: a multifunctional receptor in cholesterol homeostasis and atherosclerosis10.1016/j.tem.2017.02.001 ↗
53. Atorvastatin enhances foam cell lipophagy and promotes cholesterol efflux Through the AMP-activated protein kinase/mammalian target of rapamycin pathway10.1097/FJC.0000000000000942 ↗
54. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions10.1161/01.RES.0000028454.42385.8B ↗
55. Unique metabolic activation of adipose tissue macrophages in obesity promotes inflammatory responses10.1007/s00125-017-4526-6 ↗
56. Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy10.3390/ijms20133264 ↗
57. Protective role of phenylalanine on the ROS-induced oxidative damage, apoptosis and tight junction damage via Nrf2, TOR and NF-κB signalling molecules in the gill of fish10.1016/j.fsi.2016.11.048 ↗
58. A guide to immunometabolism for immunologists10.1038/nri.2016.70 ↗
59. Fatty acid metabolism in macrophages: a target in cardio-metabolic diseases10.1097/MOL.0000000000000370 ↗